Department of Diagnostic and Interventional Radiology, Section of Pediatric Radiology, Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Department of Diagnostic and Interventional Radiology, Section of Pediatric Radiology, Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):139-146. doi: 10.1016/j.ijrobp.2015.09.016. Epub 2015 Sep 25.
The purpose of this study was to evaluate correlations between treatment of malignancy by radiation therapy during childhood and the occurrence of thyroid gland pathologies detected by ultrasonography in follow-up examinations.
Reductions of thyroid gland volume below 2 standard deviations of the weight-specific mean value, occurrence of ultrasonographically detectable thyroid gland pathologies, and hypothyroidism were retrospectively assessed in 103 children and adolescents 7 months to 20 years of age (median: 7 years of age) at baseline (1997-2013) treated with chemoradiation therapy (with the thyroid gland dose assessable) or with chemotherapy alone and followed by ultrasonography and laboratory examinations through 2014 (median follow-up time: 48 months).
A relevant reduction of thyroid gland volume was significantly correlated with thyroid gland dose in univariate (P<.001) and multivariate analyses for doses above 2 Gy. Odds ratios were 3.1 (95% confidence interval: 1.02-9.2; P=.046) for medium doses (2-25 Gy) and 14.8 (95% confidence interval: 1.4-160; P=.027) for high doses (>25 Gy). Thyroid gland dose was significantly higher in patients with thyroid gland pathologies during follow-up (P=.03). Univariate analysis revealed significant correlations between hypothyroidism and thyroid gland dose (P<.001).
Ultrasonographically detectable changes, that is, volume reductions, pathologies, and hypothyroidism, after malignancy treatment during childhood are associated with thyroid gland dose. Both ultrasonography and laboratory follow-up examinations should be performed regularly after tumor therapy during childhood, especially if the treatment included radiation therapy.
本研究旨在评估儿童期放射治疗恶性肿瘤与超声随访检查中发现的甲状腺病变之间的相关性。
我们回顾性评估了 103 名儿童和青少年(基线时的中位年龄为 7 岁,年龄范围为 7 个月至 20 岁)在基线时(1997-2013 年)接受放化疗(甲状腺剂量可评估)或单独化疗后,通过超声和实验室检查至 2014 年(中位随访时间为 48 个月)的甲状腺体积低于体重特异性均值 2 个标准差以下、超声检测到甲状腺病变和甲状腺功能减退的情况。
单变量(P<.001)和多变量分析(剂量>2 Gy)均显示,甲状腺体积的显著降低与甲状腺剂量显著相关。中剂量(2-25 Gy)的优势比为 3.1(95%置信区间:1.02-9.2;P=.046),高剂量(>25 Gy)的优势比为 14.8(95%置信区间:1.4-160;P=.027)。在随访期间患有甲状腺疾病的患者中,甲状腺剂量显著较高(P=.03)。单变量分析显示,甲状腺功能减退与甲状腺剂量之间存在显著相关性(P<.001)。
儿童期恶性肿瘤治疗后超声可检测到的变化,即体积减少、病变和甲状腺功能减退,与甲状腺剂量有关。儿童期肿瘤治疗后,应定期进行超声和实验室随访检查,尤其是如果治疗包括放射治疗。